Another monoclonal neutralizing antibody targeting IL-1α, Bermekimab, was used in a randomized, placebo-controlled study to evaluate the efficacy of the treatment in 333 patients with advanced, metastatic colorectal cancer.46 The gene discussed is IL1A; the disease is metastatic colorectal cancer.